Cas9-DNA targeting unit chimeras

Patent metadata

Field	Value
Publication number	US-10190106-B2
Application number	US-201514976196-A
Country	US
Kind code	B2
Filing date	Dec 21, 2015
Priority date	Dec 22, 2014
Publication date	Jan 29, 2019
Grant date	Jan 29, 2019

Abstract

The present invention provides a Cas9 platform to facilitate single-site nuclease gene editing precision within a human genome. For example, a Cas9 nuclease/DNA-targeting unit (Cas9-DTU) fusion protein precisely delivers a Cas9/sgRNA complex to a specific target site within the genome for subsequent sgRNA-dependent cleavage of an adjacent target sequence. Alternatively, attenuating Cas9 binding using mutations to the a protospacer adjacent motif (PAM) recognition domain makes Cas9 target site recognition dependent on the associated DTU, all while retaining Cas9's sgRNA-mediated DNA cleavage fidelity. Cas9-DTU fusion proteins have improved target site binding precision, greater nuclease activity, and a broader sequence targeting range than standard Cas9 systems. Existing Cas9 or sgRNA variants (e.g., truncated sgRNAs (tru-gRNAs), nickases and FokI fusions) are compatible with these improvements to further reduce off-target cleavage. A robust, broadly applicable strategy is disclosed to impart Cas9 genome-editing systems with the single-genomic-site accuracy needed for safe, effective clinical application.

First claim

We claim:

1. A fusion protein comprising an attenuated Streptococcus pyogenes Cas9 (SpCas9) nuclease, said nuclease comprising a protospacer adjacent motif recognition domain having a lysine-substituted or serine substituted arginine residue and a DNA binding domain (DBD) protein.

2. The fusion protein of claim 1 , wherein said nuclease comprising a protospacer adjacent motif recognition domain having said mutated lysine-substituted or serine-substituted arginine residue is selected from the group consisting of an SpCas9 R1333K mutant (SpCas9 MT1 ), an SpCas9 R1333S mutant (SpCas9 MT2 ), and an SpCas9 R1335K mutant (SpCas9 MT3 ).

3. The fusion protein of claim 1 , wherein said DBD protein has an amino acid sequence designed to bind to a single target site.

4. The fusion protein of claim 1 , wherein said DBD protein is selected from the group consisting of a zinc finger protein and a transcription activator-like effector protein.

5. The fusion protein of claim 1 , wherein said SpCas9 nuclease is bound to a single guide RNA.

6. The fusion protein of claim 5 , wherein said single guide RNA sequence is truncated.

7. The fusion protein of claim 6 , wherein said truncated single guide RNA sequence comprises a guide sequence element that is at least sixteen nucleotides.

8. A fusion protein comprising an attenuated Streptococcus pyogenes Cas9 (SpCas9) nuclease, said nuclease comprising a protospacer adjacent motif recognition domain having a lysine-substituted or serine-substituted arginine residue and a DNA binding domain (DBD) protein, wherein said fusion protein will bind to a target site comprising a suboptimal protospacer adjacent motif sequence with improved precision compared to the attenuated nuclease alone.

9. The fusion protein of claim 8 , wherein said fusion protein further comprises a peptide linker that ranges between two and sixty amino acids.

10. The fusion protein of claim 9 , wherein said peptide linker ranges between twenty-five and sixty amino acids.

11. The fusion protein of claim 8 , wherein said nuclease comprising a protospacer adjacent motif recognition domain having said lysine-substituted or serine-substituted arginine residue is selected from the group consisting of an SpCas9 R1333K mutant (SpCas9 MT1 ), an SpCas9 R1333S mutant (SpCas9 MT2 ), and an SpCas9 R1335K mutant (SpCas9 MT3 ).

12. The fusion protein of claim 8 , wherein said DBD protein has an amino acid sequence designed to bind to a single target site.

13. The fusion protein of claim 8 , wherein said DBD protein is selected from the group consisting of a zinc finger protein and a transcription activator-like effector protein.

14. The fusion protein of claim 8 , wherein said SpCas9 nuclease is bound to a single guide RNA.

15. The fusion protein of claim 14 , wherein said single guide RNA sequence is truncated.

16. The fusion protein of claim 15 , wherein said truncated single guide RNA sequence comprises a guide sequence element that is at least sixteen nucleotides.

17. A fusion protein comprising an attenuated Neisseria meningitidis Cas9 (NmCas9) nuclease, said nuclease comprising a protospacer adjacent motif recognition domain having an alanine-substituted arginine residue and a DNA binding domain (DBD) protein, wherein said fusion protein will bind to a target site comprising a suboptimal protospacer adjacent motif sequence with improved precision compared to the attenuated nuclease alone.

18. The fusion protein of claim 17 , further comprising a peptide linker that ranges between two and sixty amino acids.

19. The fusion protein of claim 18 , wherein said peptide linker ranges between twenty-five and sixty amino acids.

20. The fusion protein of claim 17 , wherein said nuclease comprising a protospacer adjacent motif recognition domain having said alanine-substituted arginine residue is selected from the group consisting of an NmCas9 R1025A mutant (NmCas9sM) and an NmCas9 K1013A/R1025A mutant (NmCas9 DM ).

21. The fusion protein of claim 17 , wherein said DBD protein has an amino acid sequence designed to bind to a single target site.

22. The fusion protein of claim 17 , wherein said DBD protein is selected from the group consisting of a zinc finger protein and a transcription activator-like effector protein.

23. The fusion protein of claim 17 , wherein said NmCas9 nuclease is bound to a single guide RNA.

24. The fusion protein of claim 23 , wherein said single guide RNA sequence is truncated.

25. The fusion protein of claim 24 , wherein said truncated single guide RNA sequence comprises a guide sequence element that is less than twenty-two nucleotides.

26. A fusion protein comprising an attenuated Neisseria meningitidis Cas9 (NmCas9) nuclease, wherein said NmCas9 nuclease comprises a protospacer adjacent motif recognition domain comprising an alanine-substituted arginine residue and a DNA binding domain (DBD) protein.

27. The fusion protein of claim 26 , wherein said nuclease comprising a protospacer adjacent motif recognition domain having said alanine-substituted arginine residue is selected from the group consisting of an NmCas9 R1025A mutant (NmCas9 SM ) and an NmCas9 K1013A/R1025A mutant (NmCas9 DM ).

28. The fusion protein of claim 26 , wherein said DBD protein has an amino acid sequence designed to bind to a single target site.

29. The fusion protein of claim 26 , wherein said DBD protein is selected from the group consisting of a zinc finger protein and a transcription activator-like effector protein.

30. The fusion protein of claim 26 , wherein said NmCas9 nuclease is bound to a single guide RNA.

31. The fusion protein of claim 30 , wherein said single guide RNA sequence is truncated.

32. The fusion protein of claim 31 , wherein said truncated single guide RNA sequence comprises a guide sequence element that is at least sixteen nucleotides.

Assignees

• Univ Massachusetts
• Univesity Of Massachusetts

Inventors

• Wolfe Scot Andrew
• Bolukbasi Mehmet Fatih
• Gupta Ankit
• Sontheimer Erik J
• Amrani Nadia

Classifications

• C07K2319/80

  containing a DNA binding domain, e.g. Lacl or Tet-repressor · CPC title

• C12N9/22 Primary

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• C12Y301/00

  Hydrolases acting on ester bonds (3.1) · CPC title